As the first quarter of 2026 draws to a close, the advocacy team at METAvivor is navigating a complex and shifting legislative environment. From the halls of Congress to the intricacies of federal cancer registries, the organization continues to champion the needs of the metastatic breast cancer (MBC) community. This monthly update serves as a comprehensive overview of the current policy landscape, the outcomes of the recent GroundSwell virtual advocacy efforts, and the strategic initiatives designed to amplify the patient voice.
The Fiscal Year 2027 Appropriations Outlook
The federal budget cycle is an unforgiving, perpetual engine, and for METAvivor, the work for Fiscal Year (FY) 2027 is already well underway. Even as the final details of the FY 2026 landscape settle, the organization has pivoted to communicate its funding priorities to the House and Senate appropriations committees.
Legislative Priorities and Funding Requests
At the core of METAvivor’s current federal strategy is a direct appeal to lawmakers regarding the Department of Defense’s (DoD) Breast Cancer Research Program (BCRP). METAvivor has formally requested a $150 million allocation for the BCRP in the upcoming fiscal cycle. This request is not merely a number; it represents a $5 million increase over the FY 2026 levels, effectively returning the program to its FY 2024 funding benchmark.
The organization argues that this funding is critical to maintaining the momentum of innovative, high-impact research. By working in coalition with other patient advocacy groups, providers, and research institutions, METAvivor aims to build a unified front that demonstrates the broad, non-partisan support for federal investment in cancer research.
The DHS Impasse and Broader Economic Impacts
The path to the FY 2027 budget is complicated by a persistent stalemate regarding FY 2026 funding for the Department of Homeland Security (DHS). Mid-February marked the start of a partial government shutdown impacting several DHS-related entities, including the U.S. Coast Guard, the TSA, and the Secret Service.
While the "One Big Beautiful Bill" enacted earlier this year provided robust funding for Immigration and Customs Enforcement (ICE)—thereby shielding that specific agency from the current deadlock—the broader impasse remains unresolved. Policy analysts are keeping a close watch on these developments, as the gridlock on DHS, coupled with the increasing fiscal pressure from the ongoing conflict in Iran, is expected to color the tone and content of the upcoming appropriations debates. The uncertainty surrounding federal spending caps and competing national priorities poses a significant hurdle for specialized health programs that rely on consistent, annual funding increases.
Oversight and Accountability: The NIH and NCI Hearings
On March 17, the House Appropriations Committee’s Subcommittee on Labor, Health and Human Services, and Education (LHHS) held a critical oversight hearing concerning the National Institutes of Health (NIH). The hearing featured testimony from NIH Director Jay Bhattacharya, who has also been nominated to serve as the Acting Director of the Centers for Disease Control and Prevention (CDC).
Key Testimonies and Commitments
During his testimony, Dr. Bhattacharya made several high-stakes promises to lawmakers. Most notably, he pledged that the NIH would award all designated grant funding by the end of the 2026 fiscal year. To achieve this ambitious timeline, the Director of the National Cancer Institute (NCI) has been tasked with accelerating the grant approval process. Furthermore, Dr. Bhattacharya emphasized a commitment to insulating the scientific research enterprise from political interference, a point of significant interest for both sides of the aisle.
Divergent Perspectives on the Hill
The hearing highlighted a clear divide in legislative priorities:
- Republican Inquiry: Members of the committee focused their questioning on the restoration of public trust in scientific institutions and the geographic distribution of NIH funding, questioning whether federal dollars are being disseminated broadly enough across the United States.
- Democratic Inquiry: Members centered their concerns on the protection of scientific merit in grant-making, the prevention of political influence, and the need to bolster support for early-career researchers and diversity in the scientific workforce.
A particularly sharp point of contention was raised by Ranking Member Rosa DeLauro (D-CT), who criticized the current administration’s practice of "forward-funding" multi-year research grants. Rep. DeLauro noted that this strategy has resulted in a significant reduction in the total number of grants awarded in 2025, with less than 10% of research applications at the NCI receiving funding. Given that the final FY 2026 funding bill includes restrictions intended to limit this forward-funding practice, this issue is expected to remain a volatile topic in future appropriations discussions.
GroundSwell: A Virtual Advocacy Success
METAvivor’s third annual GroundSwell Virtual Advocacy Event, which launched on February 23, concluded in mid-March after a two-week extension. This extension was granted to accommodate the schedules of busy advocates, ensuring that every participant had the opportunity to hold meaningful meetings with their representatives.
Event Impact and Participant Feedback
More than 100 advocates participated in this year’s sessions. The focus of these meetings was to translate the lived experience of MBC patients into tangible legislative action. As the event closes, the advocacy team is in the process of reviewing post-meeting surveys and follow-up reports from congressional offices.
The data gathered from these interactions will serve as a roadmap for future programming. METAvivor is currently finalizing a comprehensive post-event survey, which will be distributed to all participants to gauge the effectiveness of the virtual platform and identify areas for improvement. These insights are vital for refining the strategy for the "Stampede" event scheduled for the fall and setting the stage for GroundSwell 2027.
Strategic Engagement with Cancer Registries
A major pillar of METAvivor’s long-term strategy involves ensuring that cancer data accurately reflects the reality of metastatic patients. To this end, the organization is actively building partnerships with the North American Association of Central Cancer Registries (NAACCR) and the National Cancer Registrar’s Association (NCRA).
Modernizing the SEER Registry
The National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) program and the CDC’s National Program for Cancer Registries (NCPR) are essential tools for understanding cancer trends. However, there is a recognized need to improve the sophistication of these systems.
By collaborating with NAACCR and NCRA, METAvivor is gaining deep technical knowledge regarding how these registries function and how they can be updated to better capture MBC-specific data. The goal is to advocate for systemic improvements that ensure all MBC patients are adequately represented in the data that drives research funding and clinical policy. This budding collaboration has already proven instrumental in helping METAvivor articulate what robust MBC data means to the patient community and how to modernize registry infrastructure to capture it.
Digital Transformation: Launching VoterVoice
Recognizing the need for a more agile and responsive advocacy network, the METAvivor Board has officially approved the implementation of "VoterVoice," a state-of-the-art e-advocacy tool.
Empowering the Grassroots
VoterVoice is designed to lower the barrier to entry for advocacy. Once fully operational, the system will allow METAvivor advocates to:
- Identify their specific members of Congress with a simple zip-code lookup.
- Access pre-drafted, staff-vetted letters that can be sent instantly or personalized to reflect individual patient stories.
- Track the status of their advocacy efforts in real-time.
Beyond its utility for individual advocates, VoterVoice provides the organization with powerful analytics. By understanding which geographic districts have the highest engagement and which policy issues resonate most deeply with the base, METAvivor can optimize its "grasstops" and grassroots strategies to focus on key congressional districts where their influence can have the greatest impact.
Looking Ahead: The April Agenda
As the organization moves into April, the focus remains on maintaining the momentum built during the first quarter. The upcoming month will be defined by several key initiatives:
- GroundSwell Wrap-up: Analyzing the final data from the recent virtual event to formalize best practices.
- Appropriations Advocacy: Sustaining pressure on the House and Senate to prioritize the $150 million BCRP funding request.
- Cancer Drug Parity Act: Actively promoting the introduction of this legislation in the Senate to ensure equitable access to oral cancer medications.
- Data Strategy: Continuing the development of the SEER/NCPR modernization roadmap in partnership with professional registrar organizations.
- Digital Launch: The full-scale rollout of the VoterVoice platform to the wider advocate community.
Through a combination of legislative vigilance, strategic coalition building, and the adoption of modern advocacy tools, METAvivor remains committed to its mission of securing the funding and policy changes necessary to turn the tide on metastatic breast cancer. As the fiscal year continues to evolve, the organization stands ready to adapt, ensuring that the voice of the MBC community remains heard at the highest levels of government.
About the Author
